Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Apr 18;7(5):806-13.
doi: 10.4254/wjh.v7.i5.806.

Impact of all oral anti-hepatitis C virus therapy: A meta-analysis

Siddharth Bansal  1 , Ashwani K Singal  1 , Brendan M McGuire  1 , Bhupinder S Anand  1
Affiliations

Impact of all oral anti-hepatitis C virus therapy: A meta-analysis

Siddharth Bansal et al. World J Hepatol. .

Abstract

Aim: To investigate the efficacy, safety, and cost of treatment of direct acting antivirals (DAAs) with and without peg interferon alfa2a (P), and/or ribavirin (R) in treating hepatitis C virus (HCV) genotype 1 patients.

Methods: MEDLINE was searched for randomized controlled trials (RCT) using DAAs for HCV treatment. Phase 1 trials and studies with investigational drugs on genotype 2 or 3, and on human immunodeficiency virus patients were excluded. Data were pooled for sustained virologic response (SVR), serious adverse effects, and drug discontinuation rate on various treatment arms in trials: P + R; 1(st) generation DAA (telaprevir or boceprevir) + P + R; 2(nd) generation DAA (sofosbuvir or simeprevir) + P + R; 2(nd) generation DAA + R; two 2(nd) generation DAA + R; and two 2(nd) gen DAA. Data were analyzed separately for each arm for treatment naive and non-responders (NR) to previous treatment. The cost of treatment with each regimen for achieving one SVR was also compared.

Results: Twenty three RCTs (n = 9354, 62% male, 11% cirrhosis) were analyzed. All oral (P free) regimens with combination of 2 DAA achieved SVR above 95%. The cost of treatment to achieve an SVR with DAA based regimens was lower for NR compared to P+R regimen. However, the cost per SVR remained higher for treatment naive patients.

Conclusion: Second generation and emerging DAAs are promising agents in HCV treatment, with a very high level of safety and efficacy. An important drawback is their high cost. However, the present meta-analysis shows that the cost per SVR for non responders (but not for naive patients) was lower compared to P + R. This finding together with the superior safety profile and better compliance makes these drugs highly attractive. It is possible that further reduction in treatment duration may make them even more cost effective.

Keywords: Direct acting antivirals; Hepatitis C; Hepatitis C virus; Meta-analysis; Newer agents; Oral agents.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart of the study selection for inclusion in the meta-analysis. DAA: Direct acting antivirals; RCT: Randomized controlled trial; HIV: Human immunodeficiency virus.
See this image and copyright information in PMC

References

    1. WHO Hepatitis C Guidelines. [Cited 2014 Dec 1] Available from: http: //www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en/
    1. WHO Hepatitis C Fact sheet. [Cited 2014 Dec 1] Available from: http: //www.who.int/mediacentre/factsheets/fs164/en/
    1. Freeman AJ, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR, Marinos G, Kaldor JM. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology. 2001;34:809–816. - PubMed
    1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244:359–362. - PubMed
    1. Kato N. Genome of human hepatitis C virus (HCV): gene organization, sequence diversity, and variation. Microb Comp Genomics. 2000;5:129–151. - PubMed